Intellia’s Quest with CRISPR; Innovent, S...

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Verdict for Biogen’s Long-Awaited Alzheimer’s Drug Is Finally Here   The USFDA finally gave approval to eagerly-anticipated Biogen’s Drug Aducanumab for the treatment of Alzheimer’s disease under the accelerated approval pathway. The drug, marketed under the name Aduhelm, is the first that treats an un...

Pieris Pharmaceuticals declares Respiratory and Ophthalmology deal with Genentech Pieris, a clinical-stage biotechnology company, declared that it has entered into a multi-program research collaboration and license collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise ...

Ocugen-Bharat Biotech’s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronaviru...

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. B...

Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, comprising pancreatic, colon, breast and salivary cancer, with 62.5% affected by gastrointestinal tumours. Across all 32 pati...